Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02597933




Registration number
NCT02597933
Ethics application status
Date submitted
8/10/2015
Date registered
5/11/2015
Date last updated
13/12/2019

Titles & IDs
Public title
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
Scientific title
A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Secondary ID [1] 0 0
2015-000392-28
Secondary ID [2] 0 0
1199.214
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Scleroderma, Systemic 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Nintedanib - patient receives capsules containing nintedanib twice a day

Placebo comparator: Placebo - patient receives capsules identical to those containing active drug
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks
Timepoint [1] 0 0
up to week (wk) 52 after the start of administration
Secondary outcome [1] 0 0
Absolute Change From Baseline in the Modified Rodnan Skin Score (mRSS) at Week 52
Timepoint [1] 0 0
Baseline and up to 52 weeks after the start of administration
Secondary outcome [2] 0 0
Absolute Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Week 52.
Timepoint [2] 0 0
Baseline and up to 52 weeks after the start of administration
Secondary outcome [3] 0 0
Annual Rate of Decline in FVC in Percentage (%) Predicted Over 52 Weeks
Timepoint [3] 0 0
up to 52 weeks after the start of administration
Secondary outcome [4] 0 0
Absolute Change From Baseline in FVC in mL at Week 52
Timepoint [4] 0 0
Baseline and up to 52 weeks after the start of administration
Secondary outcome [5] 0 0
Relative Change From Baseline [%] of mRSS at Week 52
Timepoint [5] 0 0
Baseline and up to 52 weeks after the start of administration
Secondary outcome [6] 0 0
Time to Death
Timepoint [6] 0 0
From date of first trial drug intake up to date of death or last contact date (ie., up to 100 weeks)
Secondary outcome [7] 0 0
The Percentage (%) of Responder Based on Combined Response Index in Systemic Sclerosis (CRISS) at Week 52
Timepoint [7] 0 0
Week 52
Secondary outcome [8] 0 0
Absolute Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco) in % Predicted at Week 52
Timepoint [8] 0 0
Baseline and up to 52 weeks after the start of administration
Secondary outcome [9] 0 0
Absolute Change From Baseline in Digital Ulcer Net Burden at Week 52
Timepoint [9] 0 0
Baseline and up to 52 weeks after the start of administration
Secondary outcome [10] 0 0
Absolute Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52
Timepoint [10] 0 0
Baseline and up to 52 weeks after the start of administration
Secondary outcome [11] 0 0
Absolute Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnoea Score at Week 52
Timepoint [11] 0 0
Baseline and up to 52 weeks after the start of administration

Eligibility
Key inclusion criteria
Inclusion criteria:

* Age >= 18 years
* 2013 American College of Rheumatology (ACR) / EULAR classification criteria for SSc fulfilled
* SSc disease onset (defined by first non-Raynaud symptom) within 7 years
* SSc related Interstitial Lung Disease confirmed by High Resolution Computer Tomography (HRCT); Extent of fibrotic disease in the lung >= 10%
* FVC >= 40% of predicted normal
* Carbon Monoxide Diffusion Capacity (DLCO) 30% to 89% of predicted normal
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

* Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) >1.5 x ULN
* Bilirubin >1.5 x ULN
* Creatinine clearance <30 mL/min
* Airway obstruction (pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1)/FVC <0.7)
* Other clinically significant pulmonary abnormalities
* Significant Pulmonary Hypertension (PH)
* Cardiovascular diseases
* More than 3 digital fingertip ulcers or a history of severe digital necrosis requiring hospitalization or severe other ulcers
* Bleeding risk (such as predisposition to bleeding, fibrinolysis, full-dose anticoagulation, high dose antiplatelet therapy, history of hemorrhagic central nervous system (CNS) event within last year
* international normalised ratio (INR) >2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by >1.5 x ULN)
* History of thrombotic event within last year
* Clinical signs of malabsorption or needing parenteral nutrition
* Previous treatment with nintedanib or pirfenidone
* Treatment with prednisone >10 mg/day, azathioprine, hydroxychloroquine, colchicine, D-penicillamine, sulfasalazine, cyclophosphamide, rituximab, tocilizumab, abatacept, leflunomide, tacrolimus, newer anti-arthritic treatments like tofacitinib and cyclosporine A, potassium para-aminobenzoate
* Unstable background therapy with either mycophenolate mofetil or methotrexate
* Previous or planned hematopoietic stem cell transplantation
* Patients with underlying chronic liver disease (Child Pugh A, B, C hepatic impairment)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/11/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
28/11/2018
Sample size
Target
Accrual to date
Final
580
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Liverpool Hospital - Sydney
Recruitment hospital [3] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [4] 0 0
St Vincent's Hospital Melbourne - Fitzroy
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2170 - Sydney
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
3065 - Fitzroy
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Maryland
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Minnesota
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Utah
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
Washington
Country [28] 0 0
United States of America
State/province [28] 0 0
Wisconsin
Country [29] 0 0
Argentina
State/province [29] 0 0
Buenos Aires
Country [30] 0 0
Argentina
State/province [30] 0 0
Ciudad Autonoma Buenos Aires
Country [31] 0 0
Argentina
State/province [31] 0 0
Florida
Country [32] 0 0
Austria
State/province [32] 0 0
Graz
Country [33] 0 0
Austria
State/province [33] 0 0
Innsbruck
Country [34] 0 0
Belgium
State/province [34] 0 0
Bruxelles
Country [35] 0 0
Belgium
State/province [35] 0 0
Gent
Country [36] 0 0
Belgium
State/province [36] 0 0
Leuven
Country [37] 0 0
Belgium
State/province [37] 0 0
Liège
Country [38] 0 0
Brazil
State/province [38] 0 0
Curitiba
Country [39] 0 0
Canada
State/province [39] 0 0
Ontario
Country [40] 0 0
Canada
State/province [40] 0 0
Quebec
Country [41] 0 0
Chile
State/province [41] 0 0
Concepción
Country [42] 0 0
Chile
State/province [42] 0 0
Talca
Country [43] 0 0
China
State/province [43] 0 0
Beijing
Country [44] 0 0
China
State/province [44] 0 0
Changchun
Country [45] 0 0
China
State/province [45] 0 0
Chengdu
Country [46] 0 0
China
State/province [46] 0 0
Hefei
Country [47] 0 0
China
State/province [47] 0 0
Shanghai
Country [48] 0 0
China
State/province [48] 0 0
Shenyang
Country [49] 0 0
China
State/province [49] 0 0
Zhuzhou
Country [50] 0 0
Czechia
State/province [50] 0 0
Prague
Country [51] 0 0
Czechia
State/province [51] 0 0
Praha 4
Country [52] 0 0
Denmark
State/province [52] 0 0
Odense
Country [53] 0 0
Denmark
State/province [53] 0 0
Århus
Country [54] 0 0
Finland
State/province [54] 0 0
Helsinki
Country [55] 0 0
Finland
State/province [55] 0 0
Turku
Country [56] 0 0
France
State/province [56] 0 0
Bobigny
Country [57] 0 0
France
State/province [57] 0 0
Bron
Country [58] 0 0
France
State/province [58] 0 0
Lille
Country [59] 0 0
France
State/province [59] 0 0
Montpellier
Country [60] 0 0
France
State/province [60] 0 0
Nantes
Country [61] 0 0
France
State/province [61] 0 0
Nice
Country [62] 0 0
France
State/province [62] 0 0
Paris
Country [63] 0 0
France
State/province [63] 0 0
Rennes
Country [64] 0 0
France
State/province [64] 0 0
Rouen
Country [65] 0 0
France
State/province [65] 0 0
Toulouse
Country [66] 0 0
France
State/province [66] 0 0
Tours
Country [67] 0 0
Germany
State/province [67] 0 0
Bad Nauheim
Country [68] 0 0
Germany
State/province [68] 0 0
Donaustauf
Country [69] 0 0
Germany
State/province [69] 0 0
Dresden
Country [70] 0 0
Germany
State/province [70] 0 0
Erlangen
Country [71] 0 0
Germany
State/province [71] 0 0
Greifswald
Country [72] 0 0
Germany
State/province [72] 0 0
Hamburg
Country [73] 0 0
Germany
State/province [73] 0 0
Hannover
Country [74] 0 0
Germany
State/province [74] 0 0
Heidelberg
Country [75] 0 0
Germany
State/province [75] 0 0
Kiel
Country [76] 0 0
Germany
State/province [76] 0 0
Köln
Country [77] 0 0
Germany
State/province [77] 0 0
München
Country [78] 0 0
Germany
State/province [78] 0 0
Münster
Country [79] 0 0
Germany
State/province [79] 0 0
Tübingen
Country [80] 0 0
Greece
State/province [80] 0 0
Athens
Country [81] 0 0
Hungary
State/province [81] 0 0
Budapest
Country [82] 0 0
India
State/province [82] 0 0
Bangalore
Country [83] 0 0
India
State/province [83] 0 0
Chandigarh
Country [84] 0 0
India
State/province [84] 0 0
Hyderabad
Country [85] 0 0
India
State/province [85] 0 0
Jaipur
Country [86] 0 0
India
State/province [86] 0 0
Mumbai
Country [87] 0 0
India
State/province [87] 0 0
Nagpur
Country [88] 0 0
India
State/province [88] 0 0
New Delhi
Country [89] 0 0
India
State/province [89] 0 0
Pune
Country [90] 0 0
India
State/province [90] 0 0
Vellore
Country [91] 0 0
Ireland
State/province [91] 0 0
Cork
Country [92] 0 0
Ireland
State/province [92] 0 0
Dublin 7
Country [93] 0 0
Israel
State/province [93] 0 0
Haifa
Country [94] 0 0
Israel
State/province [94] 0 0
Petah Tiqwa
Country [95] 0 0
Israel
State/province [95] 0 0
Tel Aviv
Country [96] 0 0
Italy
State/province [96] 0 0
Ancona
Country [97] 0 0
Italy
State/province [97] 0 0
Genova
Country [98] 0 0
Italy
State/province [98] 0 0
Monza
Country [99] 0 0
Italy
State/province [99] 0 0
Napoli
Country [100] 0 0
Italy
State/province [100] 0 0
Padova
Country [101] 0 0
Italy
State/province [101] 0 0
Roma
Country [102] 0 0
Japan
State/province [102] 0 0
Aichi, Seto
Country [103] 0 0
Japan
State/province [103] 0 0
Fukuoka, Kurume
Country [104] 0 0
Japan
State/province [104] 0 0
Hokkaido, Sapporo
Country [105] 0 0
Japan
State/province [105] 0 0
Hyogo, Himeji
Country [106] 0 0
Japan
State/province [106] 0 0
Iwate, Morioka
Country [107] 0 0
Japan
State/province [107] 0 0
Kanagawa, Kawasaki
Country [108] 0 0
Japan
State/province [108] 0 0
Kanagawa, Sagamihara
Country [109] 0 0
Japan
State/province [109] 0 0
Kanagawa, Yokohama
Country [110] 0 0
Japan
State/province [110] 0 0
Kyoto, Kyoto
Country [111] 0 0
Japan
State/province [111] 0 0
Nagasaki, Nagasaki
Country [112] 0 0
Japan
State/province [112] 0 0
Osaka, Osakasayama
Country [113] 0 0
Japan
State/province [113] 0 0
Osaka, Sakai
Country [114] 0 0
Japan
State/province [114] 0 0
Osaka, Takatsuki
Country [115] 0 0
Japan
State/province [115] 0 0
Saitama, Iruma-gun
Country [116] 0 0
Japan
State/province [116] 0 0
Shizuoka, Hamamatsu
Country [117] 0 0
Japan
State/province [117] 0 0
Tokushima, Tokushima
Country [118] 0 0
Japan
State/province [118] 0 0
Tokyo, Bunkyo-Ku
Country [119] 0 0
Japan
State/province [119] 0 0
Tokyo, Ota-ku
Country [120] 0 0
Japan
State/province [120] 0 0
Tokyo, Shinjyuku-ku
Country [121] 0 0
Malaysia
State/province [121] 0 0
Kuala Lumpur
Country [122] 0 0
Malaysia
State/province [122] 0 0
Pulau Pinang
Country [123] 0 0
Malaysia
State/province [123] 0 0
Selangor
Country [124] 0 0
Malaysia
State/province [124] 0 0
Seremban
Country [125] 0 0
Mexico
State/province [125] 0 0
Ciudad de México
Country [126] 0 0
Netherlands
State/province [126] 0 0
Amsterdam
Country [127] 0 0
Netherlands
State/province [127] 0 0
Leiden
Country [128] 0 0
Netherlands
State/province [128] 0 0
Nijmegen
Country [129] 0 0
Netherlands
State/province [129] 0 0
Rotterdam
Country [130] 0 0
Norway
State/province [130] 0 0
Oslo
Country [131] 0 0
Norway
State/province [131] 0 0
Tromsø
Country [132] 0 0
Poland
State/province [132] 0 0
Bydgoszcz
Country [133] 0 0
Poland
State/province [133] 0 0
Krakow
Country [134] 0 0
Poland
State/province [134] 0 0
Rzeszow
Country [135] 0 0
Poland
State/province [135] 0 0
Wroclaw
Country [136] 0 0
Portugal
State/province [136] 0 0
Almada
Country [137] 0 0
Portugal
State/province [137] 0 0
Amadora
Country [138] 0 0
Portugal
State/province [138] 0 0
Coimbra
Country [139] 0 0
Portugal
State/province [139] 0 0
Ponte de Lima
Country [140] 0 0
Portugal
State/province [140] 0 0
Porto
Country [141] 0 0
Portugal
State/province [141] 0 0
Vila Nova de Gaia
Country [142] 0 0
Spain
State/province [142] 0 0
Barcelona
Country [143] 0 0
Spain
State/province [143] 0 0
Madrid
Country [144] 0 0
Spain
State/province [144] 0 0
Santander
Country [145] 0 0
Spain
State/province [145] 0 0
Valencia
Country [146] 0 0
Spain
State/province [146] 0 0
Vigo
Country [147] 0 0
Sweden
State/province [147] 0 0
Gothenburg
Country [148] 0 0
Switzerland
State/province [148] 0 0
St. Gallen
Country [149] 0 0
Switzerland
State/province [149] 0 0
Zürich
Country [150] 0 0
Thailand
State/province [150] 0 0
Hat Yai
Country [151] 0 0
Thailand
State/province [151] 0 0
Muang
Country [152] 0 0
Thailand
State/province [152] 0 0
Ratchathewi
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Glasgow
Country [154] 0 0
United Kingdom
State/province [154] 0 0
London
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Systemic Sclerosis (SSc) is a devastating disease of unknown etiology. Patients suffer from multiple organ fibrosis whereas lung fibrosis (interstitial lung disease, ILD) is one of the main driver for mortality. There is preclinical evidence for efficacy of nintedanib in SSc and associated ILD (SSc-ILD) and the anti-fibrotic efficacy of nintedanib was proven in idiopathic pulmonary fibrosis patients, who are presenting a similar pattern regarding lung fibrosis. Hence it is the purpose of the trial to confirm the efficacy and safety of nintedanib 150 mg bid in treating patients with SSc-ILD, compared with placebo. The trial will be conducted as a double blind, randomised, placebo-controlled trial with primary efficacy evaluation at week 52 and placebo-controlled treatment until last patient out (up to a maximum of 100 weeks). Respiratory function is globally accepted for assessment of treatment effects in patients with lung fibrosis. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in patients with SSc-ILD.
Trial website
https://clinicaltrials.gov/study/NCT02597933
Trial related presentations / publications
Denton CP, Goh NS, Humphries SM, Maher TM, Spiera R, Devaraj A, Ho L, Stock C, Erhardt E, Alves M, Wells AU. Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. Rheumatology (Oxford). 2023 May 2;62(5):1870-1876. doi: 10.1093/rheumatology/keac535.
Maher TM, Bourdin A, Volkmann ER, Vettori S, Distler JHW, Alves M, Stock C, Distler O. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects. Respir Res. 2022 Jul 5;23(1):178. doi: 10.1186/s12931-022-02095-6.
Kreuter M, Hoffmann-Vold AM, Matucci-Cerinic M, Saketkoo LA, Highland KB, Wilson H, Alves M, Erhardt E, Schoof N, Maher TM. Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2023 Feb 6;62(SI):SI43-SI53. doi: 10.1093/rheumatology/keac325.
Volkmann ER, Kreuter M, Hoffmann-Vold AM, Wijsenbeek M, Smith V, Khanna D, Denton CP, Wuyts WA, Miede C, Alves M, Sambevski S, Allanore Y. Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial. Rheumatology (Oxford). 2022 Nov 2;61(11):4397-4408. doi: 10.1093/rheumatology/keac091.
Kreuter M, Del Galdo F, Miede C, Khanna D, Wuyts WA, Hummers LK, Alves M, Schoof N, Stock C, Allanore Y. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. Arthritis Res Ther. 2022 Jan 10;24(1):19. doi: 10.1186/s13075-021-02710-9.
Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM; SENSCIS trial investigators. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021 Jan;9(1):96-106. doi: 10.1016/S2213-2600(20)30330-1.
Roennow A, Sauve M, Welling J, Riggs RJ, Kennedy AT, Galetti I, Brown E, Leite C, Gonzalez A, Portales Guiraud AP, Houyez F, Camp R, Gilbert A, Gahlemann M, Moros L, Luna Flores JL, Schmidt F, Sauter W, Finnern H. Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations. BMJ Open. 2020 Dec 16;10(12):e039473. doi: 10.1136/bmjopen-2020-039473.
Azuma A, Chung L, Behera D, Chung M, Kondoh Y, Ogura T, Okamoto M, Swarnakar R, Zeng X, Zou H, Meng X, Gahlemann M, Alves M, Kuwana M; SENSCIS trial investigators. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial. Respir Investig. 2021 Mar;59(2):252-259. doi: 10.1016/j.resinv.2020.10.005. Epub 2020 Nov 19.
Maher TM, Mayes MD, Kreuter M, Volkmann ER, Aringer M, Castellvi I, Cutolo M, Stock C, Schoof N, Alves M, Raghu G; SENSCIS Trial Investigators. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2021 Apr;73(4):671-676. doi: 10.1002/art.41576. Epub 2021 Mar 8.
Kuwana M, Ogura T, Makino S, Homma S, Kondoh Y, Saito A, Ugai H, Gahlemann M, Takehara K, Azuma A. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial. Mod Rheumatol. 2021 Jan;31(1):141-150. doi: 10.1080/14397595.2020.1751402. Epub 2020 Apr 23.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20.
Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, Varga J, Coeck C, Gahlemann M, Sauter W, Schmidt H, Highland KB; SENSCIS trial investigators. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS). Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):75-81. Epub 2017 Jun 29.
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02597933